Beyond GLP-1, Novo eyes next-gen obesity drugs: Vikrant Shrotriya | People
Semaglutide’s patent expiry has generated enormous discussion in India. Where does Novo Nordisk stand two months…
Novo Nordisk’s Pipeline Deepens as Amycretin and MASH Data Bolster a Stretched Stock
Novo Nordisk advances metabolic disease pipeline with Semaglutide success in MASH, high-dose Wegovy weight loss data, and Amycretin…
Novo Nordisk Presses Forward With Oral Semaglutide and Amycretin as CagriSema Nears FDA Verdict
Novo Nordisk awaits FDA decisions on CagriSema and oral Ozempic, expands paediatric GLP-1 approvals, and advances Amycretin for…